Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Lung Cancer
•
Thoracic Malignancies
•
Medical Oncology
Is there a role for pemetrexed in the treatment of metastatic adenosquamous NSCLC?
Related Questions
Can Dupixent and Durvalumab be used at the same time in a patient with extensive stage small cell lung cancer?
Given potential long-term CV toxicity concerns with lorlatinib and data suggesting that dose reduction does not compromise efficacy, do you ever recommend initiating and/or maintaining lower-dose lorlatinib in ALK+ NSCLC?
When will you select Dato-DXd for patients with EGFR-mutated non-small cell lung cancer?
In light of the 2024 Shkreli Awards, how do you address patient concerns regarding the 240 mg versus 960 mg dose of sotorasib?
What are your top takeaways in Thoracic Cancers from ASCO 2025?
Does receipt of chemoimmunotherapy for LS-SCLC impact your recommendation for PCI?
How do you approach treatment selection for patients with non-small cell lung cancer who have uncommon EGFR mutations compared to those with common mutations?
How do you approach treatment selection among novel bispecific antibodies and ADCs for patients with EGFR+ NSCLC previously treated with 3rd generation EGFR inhibitors?
Does anyone have experience obtaining sunvozertinib in the second line setting for patients with EGFR exon 20 insertion mutations?
Would you offer a RET inhibitor to a patient with de novo metastatic, RET V706M mutant squamous cell lung cancer?
